UK markets close in 8 hours 27 minutes
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • FTSE 250

    22,646.08
    0.00 (0.00%)
     
  • AIM

    1,182.30
    0.00 (0.00%)
     
  • GBP/EUR

    1.1736
    +0.0046 (+0.39%)
     
  • GBP/USD

    1.3236
    +0.0001 (+0.01%)
     
  • BTC-GBP

    36,710.31
    -769.31 (-2.05%)
     
  • CMC Crypto 200

    1,241.22
    -200.54 (-13.91%)
     
  • S&P 500

    4,538.43
    -38.67 (-0.84%)
     
  • DOW

    34,580.08
    -59.72 (-0.17%)
     
  • CRUDE OIL

    67.86
    +1.60 (+2.41%)
     
  • GOLD FUTURES

    1,782.90
    -1.00 (-0.06%)
     
  • NIKKEI 225

    27,927.37
    -102.20 (-0.36%)
     
  • HANG SENG

    23,359.28
    -407.41 (-1.71%)
     
  • DAX

    15,169.98
    -93.12 (-0.61%)
     
  • CAC 40

    6,765.52
    0.00 (0.00%)
     

Will a Powerful Acquisition Make This Early 2021 IPO a Buy?

·5-min read
Will a Powerful Acquisition Make This Early 2021 IPO a Buy?
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Bioventus (NASDAQ: BVS) is a company that specializes in developing innovations in biologics and clinical therapies for active healing. In February of this year, Bioventus opened its doors of ownership to the public by way of an IPO of 8 million shares. Leading up to the spin-off, Smith & Nephew was experiencing strong growth from the biologics and clinical therapies unit, with annual revenue growing from $52 million in 2004 to $223 million in 2010 for that unit alone.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting